Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancers Congress 2025
— Promisingmonotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designation — New clinical response observed in PD-1 resistantgastroesophageal junction (GEJ) tumor — Invikafusp alfa demonstrates overall Disease Control Rate of 63%, Tumor Regression […]